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Although many recombinant adenovirus vectors (rAd) have been developed, especially by using group C
adenoviruses, to transfer and express genes, such rAd do not readily infect B-cell lines due to the lack of the
coxsackievirus-adenovirus receptor. Bispecific antibodies have been used in different cell systems to facilitate
entry of rAd into otherwise nonpermissive cells. Bispecific antibody is synthesized by covalently linking two
monoclonal antibodies with distinct specificities. It has been shown that lymphoproliferative tumors commonly
express the cell surface protein CD70, while this receptor is normally expressed on only a small subset of highly
activated B cells and T cells. We therefore investigated whether a bispecific antibody with specificities for the
adenovirus fiber protein and CD70 can facilitate rAd entry and subsequent expression of rAd-encoded genes
in CD70-positive B cells. We found high CD70 expression on Epstein-Barr virus (EBV)-transformed lympho-
blastoid cell lines (LCLs), as well as some, but not all, Burkitt lymphoma (BL) lines. We show here that rAd
encoding green fluorescent protein (Ad-GFP) infects EBV-transformed LCLs and a CD70-positive BL line 10-
to 20-fold more efficiently in the presence of the CD70-fiber bispecific antibody. In contrast, the bispecific
antibody does not enhance Ad-GFP infection in CD70-deficient BL cells. Using the CD70-fiber bispecific
antibody, we increased the ability of rAd vectors encoding the EBV immediate-early proteins BZLF1 and
BRLF1 to induce the lytic form of EBV infection in LCLs. These results indicate that the CD70-fiber bispecific
antibody can enhance rAd infection of CD70-positive B cells and suggest the use of this vector to explore
EBV-positive LCLs.
The consistent presence of the Epstein-Barr virus (EBV)
genome in certain malignancies, particularly its nearly univer-
sal presence in AIDS-related central nervous system lympho-
mas (4, 6, 29) and nasopharyngeal carcinomas (31), suggests
that EBV itself could serve as a target for the preferential
killing of tumor cells using gene delivery methods. Although
the use of adenovirus vectors expressing EBV-specific toxins
could potentially be useful for treating EBV-positive epithelial
cell tumors, EBV-associated B-cell tumors are unlikely to be
susceptible to conventional adenovirus-mediated delivery. The
recently identified adenovirus receptor for serogroups 2 and 5,
the coxsackievirus-adenovirus receptor (CAR), is not ex-
pressed in most hematologic cell lines (19, 28, 44), and conse-
quently, adenovirus delivery to most B-cell lines is extremely
inefficient. Nevertheless, other advantageous aspects of recom-
binant adenovirus vectors (rAd), including the extremely high
achievable titers and the large size (10 kb) of the gene inserts
tolerated, continue to make rAd the most attractive currently
available gene delivery vectors. Therefore, there has been in-
tense interest in modifying rAd to improve their delivery into
hematopoietic cell types.
Bispecific antibodies (BsAb) are covalently linked antibod-
ies with distinct specificities (40). BsAb can extend a virus’s
normal tropism by using specific antibodies to the virus’s re-
ceptor (the fiber protein, in the case of adenovirus [41]) and an
alternate cellular ligand. For example, the delivery of rAd with
a FLAG epitope-modified adenovirus fiber protein to T cells
was shown to be greatly enhanced when a bispecific antibody
directed against the FLAG epitope and the T-cell-specific CD3
cell surface receptor (48) was used. The method has been
applied to other virus-cell surface ligand systems (5, 7, 49).
In this study, we have investigated the use of an anti-CD70–
antifiber BsAb to enhance adenovirus delivery to CD70-posi-
tive B-cell lines. CD70 expression is usually limited to a small
subset of highly activated B and T cells (42). In contrast,
EBV-immortalized B cells (lymphoblastoid cell lines [LCLs])
routinely express CD70 (42), as do a number of EBV-positive,
as well as EBV-negative, B-cell lymphomas (17, 27). Expres-
sion of CD70 (which has been identified as the CD27 ligand)
on T cells appears to have a physiological role in inducing
CD271 B cells to proliferate and differentiate into plasma cells
(2), while on B cells, CD70 seems to have a costimulatory effect
upon T cells (3). Interestingly, although CD70 expression in
vivo is usually limited to a few highly activated B cells and T
cells, CD70 is also expressed in EBV-positive nasopharyngeal
carcinomas (1, 31). Thus, CD70 expression could potentially
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serve as a relatively specific marker with which to direct ade-
novirus vectors to many EBV-infected cells and/or LCLs.
Here we show that BsAb directed against the CD70 receptor
and the adenovirus fiber protein (BsAb-CD70-fiber) signifi-
cantly enhance adenovirus delivery to CD70-positive, but not
CD70-negative, cell lines. By using this technique, we can ef-
fectively transfer genes to EBV-positive LCLs, including genes
that induce the EBV lytic cycle. Our group has previously
shown that adenovirus vectors expressing the EBV immediate-
early (IE) protein BZLF1 or BRLF1 can induce the lytic form
of EBV infection in EBV-positive tumors in vivo, thereby re-
sulting in specific killing of tumor cells (47). However, by using
methods including lipofection and electroporation, we have
been previously unable to demonstrate that BRLF1 expression
in LCLs induces lytic EBV infection (50), perhaps due to
inefficient delivery of BRLF1. Using BsAb-CD70-fiber, we now
demonstrate that the EBV BRLF1 IE protein (as well as the
BZLF1 protein) induces the lytic form of EBV infection in
LCLs. Thus, use of the CD70-fiber bispecific antibody may be
a useful approach by which to enhance the delivery of rAd to
CD70-positive cell lines.
MATERIALS AND METHODS
Cell lines. LCLs were obtained by transforming primary human B cells from
different donors with the B958 strain of EBV. Raji, Jijoye, P3HR1, and Akata
cells are derived from various EBV-positive Burkitt lymphomas (BLs). DG75
cells are an EBV-negative BL cell line. A9 cells are a murine epithelioid fibro-
blast cell line. The culture medium used was RPMI medium (for all suspension
cells) or Dulbecco modified Eagle medium (for A9 cells) with 10% fetal bovine
serum at 37°C with 4% CO2 and 100% humidity.
Adenovirus vectors. The recombinant adenoviruses used in this study have
been previously developed and described (47). In brief, the relevant gene was
cloned into an adenovirus shuttle vector, and Cre-Lox-mediated recombination
between the shuttle vector and a replication-deficient type 5 adenovirus genome
with E1 and E3 deleted resulted in the recombinant adenovirus. Expression of
each gene of interest is driven by the cytomegalovirus IE promoter. Recombinant
adenoviruses were propagated in 293 cells by using initial stocks provided by the
UNC Gene Therapy Core facility.
BsAb. The anti-CD70 monoclonal antibody (MAb) Ki-24 used to construct the
anti-CD70–antifiber BsAb was produced from a hybridoma cell line that was a
gift from H. Stein. The anti-CD70-antifiber BsAb were made, as previously
described, by using succinimidyl-3-(2-pyridyldithiol)-propionate (SPDP) as a
cross-linking agent (40, 49). Briefly, a fourfold molar excess of SPDP was added
to 0.5 mg each of the neutralizing 7H11 antifiber knob MAb and the Ki-24
anti-CD70 MAb in borate-buffered solution (BBS), pH 8.5. After 30 min at room
temperature, the pH of Ki-24 was lowered by addition of 0.1 volume of 1 M
sodium acetate, pH 4.5, and 1 mg of solid dithiothreitol was added. After 5 min
at room temperature, the reduced Ki-24 was passed over a Pharmacia PD10
disposable Sephadex G-25 column in BBS and added to the SPDP-treated
antifiber MAb. Cross-linking was allowed to proceed for 1 h at room tempera-
ture, and the protein was concentrated to 0.3 ml and fractionated on an HR 10/30
Superose 12 column (Pharmacia) in BBS. Monomeric immunoglobulin G (ap-
proximately 50%) was discarded, and the cross-linked material was pooled. It
consisted of about 50% dimer, and the rest was higher-molecular-weight aggre-
gates. The final BsAb product had a concentration of 0.063 mg/ml and was
estimated to contain 1.2 3 1011 molecules per ml.
BsAb-adenovirus infection. To infect cells with rAd, 106 cells were washed
three times in Dulbecco modified Eagle medium-F12 medium (prechilled to 4°C)
and incubated for 30 min on ice. One million cells per sample were collected in
a 15-ml conical tube, and the cells were then pelleted in a centrifuge. The pellets
were then resuspended in 100 ml of medium in the presence or absence of BsAb
(0.63 mg/ml unless otherwise indicated) and incubated on ice for 1.5 to 2 h with
manual resuspension every 10 min. All samples were then washed three times
with medium, pelleted, resuspended in 100 ml with a given rAd (multiplicity of
infection [MOI] of 20:1 unless otherwise indicated) or plain medium, and incu-
bated on ice for 1.5 to 2 h as before. Finally, the cells were resuspended in 1.4 ml
of RPMI medium with 10% fetal bovine serum and cultured for 24 to 48 h before
further analysis. In some experiments, the BsAb was, instead, preincubated with
virus at 4°C for 1 h and then further incubated with cells for 1 h at 4°C before
culturing for 24 to 48 h in 1.4 ml of RPMI medium.
FACS. Cells to be examined for green fluorescent protein-associated fluores-
cence were trypsinized, if adherent, and then washed three times with phosphate
buffered saline (PBS) with 1% (wt/vol) bovine serum albumin. Finally, they were
resuspended in 0.5 to 1 ml of PBS and analyzed for relative fluorescence using a
Becton-Dickinson FACScan flow cytometer. Cells to be studied for the presence
of CD70 were fixed using ice-cold 60% acetone for 10 min and then washed three
times with PBS-bovine serum albumin. Cells were next incubated in a 1:100
dilution of the Ki-24 MAb at room temperature for 1 h and rewashed three
times. The fluorescein isothiocyanate-conjugated secondary antibody was ap-
plied for 1 h at room temperature in the dark, and cells were washed three more
times. Finally, the cells were resuspended in 0.5 to 1 ml of PBS and analyzed by
fluorescence-activated flow cytometry (FACS).
To quantitate CD70 receptor expression, a 1:100 dilution of anti-CDw70
(Pharmingen) and an equal concentration of an isotype control were used for
FACS. A 1:100 dilution of fluorescein isothiocyanate-conjugated goat anti-
mouse immunoglobulin G (Sigma) was used for immunofluorescence and FACS
studies.
Western blot analysis. Tissue culture samples were collected and washed in
PBS three times. Cells were resuspended in 40 to 80 ml of lysis buffer (0.25 M
NaCl, 0.1% NaPO4, 0.05 M HEPES, 0.005 EDTA) containing fresh 13 protease
inhibitor (Complete; Boehringer) and rapidly freeze-thawed three times. Cellu-
lar debris was removed by centrifugation in a tabletop microcentrifuge at 14,930
3 g for 15 min at 4°C, and the protein concentration was determined by a
Bradford assay. Between 40 and 100 mg of total cellular protein was loaded onto
a 10% denaturing polyacrylamide gel, and immunoblot analysis was subsequently
performed using anti-BZLF1 and anti-BRLF1 (Argenene) antibodies (both were
used at a 1:100 dilution) or anti-BMRF1 (Capricorn, Scarborough, Maine) (also
used at a 1:100 dilution) and the ECL detection kit (Amersham Pharmacia).
RESULTS
CD70 is expressed on a variety of EBV-positive B-cell lines.
To examine whether CD70 is expressed on a variety of differ-
ent EBV-positive B-cell lines, we used FACS. The levels of cell
surface CD70 expression on three different EBV-transformed
B-cell LCLs (LCL-1, LCL-2, and LCL-3), four different EBV-
positive BL cell lines (Jijoye, Raji, P3HR1, and Akata), and an
EBV-negative BL cell line (DG75) were determined by com-
paring the level of fluorescence of cells stained with a MAb to
CD70 with that of cells stained with an isotype control antibody
(Fig. 1). A9 cells (a murine epithelioid fibroblast line) served as
a negative control in these experiments.
As shown in Fig. 1, LCLs derived from three different indi-
viduals each expressed a high level of CD70. Of the EBV-
positive BL cell lines tested, three (Raji, Jijoye, and P3HR1)
expressed high levels of CD70, although one (Akata) expressed
essentially no CD70. The EBV-negative DG75 BL cell line also
expressed a high level of CD70. As expected, A9 cells stained
negative for CD70.
Interestingly, each of the EBV-positive cell lines shown to
express a high level of the CD70 receptor has type III EBV
latency (in which nine different EBV genes are expressed) (36).
In contrast, Akata cells, which have type I latency (character-
ized by viral gene expression restricted to expression of the
EBNA 1, BamHI-A, and EBER transcripts [24, 36]), have no
CD70 expression. This suggests that neither type I EBV infec-
tion nor c-myc translocation (which occurs in all BLs) is suffi-
cient to induce CD70 activation.
BsAb-CD70-fiber targets adenovirus vector-BsAb to CD701
cells. We next examined whether BsAb containing antibodies
directed against CD70 and the adenovirus fiber protein (BsAb-
CD70-fiber) increases the efficiency of rAd infection in CD70-
positive cell lines. A rAd expressing the green fluorescent pro-
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tein (AdGFP) under the control of the cytomegalovirus IE
promoter was used to infect LCLs (LCL-1 line) and the CD70-
positive Raji BL line in the presence or absence of BsAb.
Adenovirus infection of cells was assessed by quantitating the
level of green fluorescence using flow cytometry (Fig. 2). At an
MOI of 20, AdGFP did not efficiently infect either LCL-1 or
Raji cells, although at this MOI, AdGFP infected virtually
100% of HeLa cells (data not shown). Preincubation of cells
with BsAb alone, in the absence of AdGFP, did not increase
the percentage of fluorescent B cells. However, when either
Raji or LCL-1 cells were preincubated with the combination of
BsAb and AdGFP, a significant percentage of the cells (10 to
20%) were fluorescent (Fig. 2A). Preincubation of the adeno-
virus with BsAb and subsequent infection of the cells also
resulted in improved transduction of CD70 cells (Fig. 2B).
These results indicate that BsAb-CD70-fiber increases adeno-
virus infectivity in CD70-positive B-cell lines 10- to 20-fold.
BsAb-CD70-fiber does not target adenovirus vector to
CD702 cells. If the BsAb-CD70-fiber targets rAd to CD70,
then adenovirus gene transfer into CD70-negative cell lines
should not be augmented by BsAb. To confirm that this is the
case, we compared the levels of infectivity of AdGFP in a
CD70-negative BL line (Akata) in the presence and absence of
BsAb-CD70-fiber. Although Akata cells are intrinsically more
susceptible to adenovirus transduction than either Raji or
LCL-1 cells in the absence of BsAb, the addition of BsAb-
CD70-fiber did not increase the level of AdGFP transduction
in Akata cells at an MOI of either 20 or 50 (Fig. 3). Therefore,
BsAb-CD70-fiber does not enhance adenovirus transduction in
B-cell lines lacking CD70.
Dose-response relationship of BsAb-CD70-fiber. Although
BsAb-CD70-fiber increased rAd delivery to LCL-1 and Raji
cells 10- to 20-fold, we were still unable to transduce the
majority of cells using rAd at an MOI of 20 (Fig. 2). The
relative inefficiency of BsAb-CD70-fiber rAd delivery may re-
flect the fact that there are only 250 high-affinity CD70 recep-
tors on EBV-transformed lymphoblasts (14), versus 3,000 to
10,000 CARs on HeLa cells (11, 18, 32). In an effort to increase
the number of cells transduced, we examined the effect of
raising the concentration of BsAb from 0.6 to 1.2 mg/ml upon
AdGFP transduction into LCL-1 and Raji cells (Fig. 4). In-
creasing the concentration of BsAb from 0.6 to 1.2 mg/ml
FIG. 1. Expression of CD70 on LCLs and BLs. The presence of
surface CD70 in various cell lines was quantitated by FACS. (A) The
level of fluorescence of Raji cells stained with a CD70 antibody versus
that of Raji cells stained with an isotype control antibody is shown. (B)
A bar graph of the percentage of CD70-positive stained cells is shown
using three LCLs (LCL-1, -2, and -3), three type III latency EBV-
positive BL lines (Jijoye, Raji, and P3HR1), an EBV-negative BL line
(DG75), a type I latency EBV-positive BL line (Akata), and a murine
epithelioid fibroblast line (A9).
FIG. 2. BsAb increase adenovirus delivery to CD701 cells. (A)
LCL-1 or Raji cells (106) were pretreated with either medium alone or
CD70-fiber BsAb (0.6 mg/ml) for 2 h on ice. Cells were then treated
with AdGFP (a recombinant adenovirus vector that expresses the
green fluorescent protein) at an MOI of 20 for 2 h. The cells were
washed and cultured for 2 days in a 24-well plate. Cells were then
examined by FACS for green fluorescence. (B) Raji cells were first
exposed to BsAb and then washed and subsequently incubated with
AdGFP (as for panel A) (first four columns), or alternatively, BsAb
were first preincubated with AdGFP on ice for 1 h and this mixture was
then incubated with the cells (results shown in the last column labeled
with asterisks).
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produced only a small increase in the percentage of AdGFP-
infected cells. Since we estimated that a BsAb dose of 0.6
mg/ml already contains over 100 molecules of BsAb per CD70
receptor, as well as over 100 molecules of BsAb per adenovirus
particle, the failure of an increased dose of BsAb to enhance
the infectivity of CD70-positive cells is not particularly surpris-
ing. Higher doses of BsAb were associated with increasing
levels of cytotoxicity in the absence of rAd. In addition, in-
creasing the AdGFP MOI to 500 did not significantly enhance
AdGFP transduction of Raji cells (data not shown). Thus, the
inability to infect all Raji and LCL-1 cells using the CD70-fiber
bispecific antibody cannot readily be overcome by simply in-
creasing the concentration of bispecific antibody or adenovirus
vector and may, instead, reflect a level of expression of the
CD70 receptor inadequate to mediate adenovirus entry into a
portion of these cells. We cannot completely exclude the pos-
sibility that not all antibody-virus complexes are infectious due
to steric hindrance.
CD70 specificity in BsAb is required for enhanced transduc-
tion of LCL-1 cells. If BsAb-CD70-fiber functions as expected,
then we would anticipate that BsAb containing the adenovirus
fiber antibody linked to an irrelevant antibody (directed
against the influenza virus hemagglutinin [HA] epitope) would
not be able to mediate adenovirus entry into CD70-positive
cell lines. As shown in Fig. 5, this prediction is indeed the case.
The bispecific HA-fiber antibody did not enhance transduction
of the AdGFP vector into LCL-1 cells, while the CD70-fiber
BsAb did show enhancement of gene transfer. In contrast, the
HA-fiber BsAb does increase adenovirus entry into cells con-
stitutively expressing an HA-tagged receptor (Ray Pickles, un-
published data). Thus, as expected, the ability of BsAb-CD70-
fiber to mediate adenovirus entry into B cells requires both the
CD70 receptor and the CD70 component of the antibody.
BsAb-CD70-fiber enhances delivery of EBV IE genes by ad-
enovirus vectors into LCLs. A major interest of our laboratory
has been the development of gene delivery methods by which
to induce EBV-dependent cell killing (23). However, we have
previously been unable to efficiently deliver genes into LCLs by
using a variety of methods (electroporation, lipofection, or
adenovirus delivery). We thus examined whether BsAb-CD70-
fiber can enhance the delivery of rAd vectors encoding the
EBV IE proteins BZLF1 and BRLF1 into EBV-positive LCLs.
LCL-1 cells were infected with the adenovirus-BZLF1 (AdZ)
(Fig. 6A) or adenovirus-BRLF1 (AdR) (Fig. 6B) vector in the
presence or absence of bispecific CD70-fiber antibody. As a
control, an adenovirus vector expressing the b-galactosidase
gene (AdLacZ) was also used to infect LCL-1 cells in the
presence of bispecific antibody. The levels of BZLF1 and
BRLF1 expression were quantitated by immunoblot analysis of
infected cells. Both the BZLF1 and BRLF1 rAd vectors pro-
duced substantially more protein in LCL-1 cells in the pres-
ence of BsAb. Actin staining of the immunoblots confirmed
equal protein loading. Thus, BsAb-CD70-fiber can be used to
allow BZLF1 and BRLF1 delivery to EBV-positive LCLs in
vitro.
BsAb-CD70-fiber-mediated expression of BZLF1 or BRLF1
induces lytic EBV infection in LCLs. Although it is clear that
both BZLF1 and BRLF1 can induce the lytic form of EBV
infection in certain BL lines (8, 33, 34, 47), as well as in
EBV-positive epithelial cell lines (50), the ability of BZLF1
and BRLF1 to induce the lytic form of EBV replication in
LCLs has been somewhat controversial (8, 50), perhaps due to
the lack of an efficient system of delivery to these cells. We
previously reported that transfected BRLF1 did not induce the
lytic form of EBV replication in two different LCL lines, but
FIG. 3. CD70-fiber BsAb do not enhance AdGFP infection in
CD702 cells. Akata cells, with or without CD70-fiber BsAb (0.6 mg/
ml), were infected with different MOIs of AdGFP. Green fluorescence
of cells was quantitated by FACS.
FIG. 4. Dose-response relationship of CD70-fiber BsAb and AdGFP
entry. LCL-1 and Raji cells were exposed to various concentrations of
CD70-fiber BsAb, infected with AdGFP, and incubated for 2 days. The
percentage of cells expressing GFP was quantitated by FACS.
FIG. 5. CD70 specificity of BsAb is required for enhanced infection
of LCL-1 cells. LCL-1 cells were exposed to no BsAb, CD70-fiber
BsAb, or negative control (HA-fiber) BsAb. Each sample was then
washed and exposed to either medium alone or AdGFP. The percent-
age of cells expressing GFP was quantitated by FACS after 2 days of
incubation.
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these negative results could potentially have resulted from
insufficient transfection efficiency (50). We therefore used
BsAb-CD70-fiber to reexamine the effect of BZLF1 and
BRLF1 expression in LCLs. As shown in Fig. 7, both the AdZ
and AdR vectors induced expression of the lytic EBV protein
BMRF1 in the presence, but not in the absence, of BsAb-
CD70-fiber, whereas the control AdLacZ combined with BsAb
had no effect. These results thus clearly show that both BZLF1
and BRLF1 can induce the lytic form of EBV infection in
LCLs. Furthermore, the inclusion of the bispecific CD70-fiber
antibody was required for BMRF1 expression.
DISCUSSION
Adenovirus vectors have many attractive features (such as
very high viral titers and the accommodation of large gene
inserts) that are not currently available when other vectors are
used. However, many hematopoietic cell types are not readily
infectible by conventional adenovirus vectors, primarily due to
insufficient CAR expression (28). In this study, we have created
BsAb directed against the adenovirus fiber protein and a cel-
lular receptor, CD70, which is expressed on highly activated B
cells and T cells. We demonstrated that these BsAb specifically
and significantly enhance adenovirus infection of CD70-posi-
tive, but not CD70-negative, B-cell lines. Thus, this method
should prove useful for specifically increasing delivery of ade-
novirus vectors to CD70-positive cells.
The primary receptor of the fiber protein for adenovirus
serotypes 2 and 5 has been identified (CAR) (37, 44). The
CAR protein interacts with the knob domain of the adenovirus
fiber protein to mediate initial attachment of the virus to the
cell (38). Adenovirus internalization is also significantly en-
hanced by the presence of avb3/5 integrins, which interact with
the virus penton base (20, 30). EBV infection of B cells has
been reported to increase av integrin expression (21), as well as
increase the efficiency of adenovirus infection (22). Neverthe-
less, because the CAR protein is not present in lymphocyte
lineages, EBV-positive LCLs still remain highly resistant to
adenovirus infection. As shown in this report, the use of a
conventional adenovirus vector at an MOI of 20 to 50 results in
gene delivery to, at most, 1 to 2% of EBV-positive LCLs, in
contrast to essentially 100% delivery to a variety of CAR-
positive epithelial lines.
A variety of methods are currently being tested as ways to
increase the delivery of adenovirus vectors to lymphocytes.
Modification of the fiber protein has been used successfully to
broaden adenovirus tropism to alternative cellular receptors
(13), and a similar approach could potentially be used to target
adenovirus infection to a lymphocyte-specific receptor. Alter-
nately, Curiel et al. have shown that adenovirus particles can
transduce plasmid DNA that has been coupled to the capsid
exterior into LCLs, transducing up to 60% of cells; however, an
MOI of 1,000 to 3,000 was required for this level of efficiency
(10). Other studies have likewise required MOIs of 100 to 500
in order to gain entry in LCLs (21, 22). By using another
approach, an adenovirus type 3-pseudotyped vector has been
shown to infect LCLs 10 times more efficiently than a control
vector pseudotyped with adenovirus type 5 (the serotype used
in the prototype adenovirus vectors [46]). When 5,000 to
50,000 particles per cell were used, serotype 3-derived vectors
could transduce genes into 20 to 50% of LCLs (46). Neverthe-
less, adenovirus type 3-derived vectors also deliver genes to
non-LCLs as well (43) and thus cannot be used to specifically
deliver toxic genes to lymphoid cells.
We report here the first attempt to target the cellular CD70
receptor for specific gene delivery. The CD70 receptor could
potentially be used to induce relatively specific killing of ma-
FIG. 6. CD70-fiber BsAb enhance AdZ and AdR entry into LCL-1
cells. (A) LCL-1 cells, with or without CD70-fiber BsAb, were either
mock infected, infected with AdZ, or infected with AdLacZ. All in-
fections were done at an MOI of 20. After 2 days, immunoblot assays
were performed on extracts from each sample, followed by staining
with a MAb against BZLF1. Staining for b-actin was used to ensure
equal sample loading. (B) LCLs, with or without CD70-fiber BsAb,
were mock infected, infected with AdR, or infected with AdLacZ.
After 2 days, immunoblot assays were performed on extracts from each
sample, followed by staining with a MAb against BRLF1 or actin. NS
indicates a nonspecific band.
FIG. 7. BsAb-enabled expression of BZLF1 and BRLF1 induces
BMRF1 in LCLs. LCL-1 cells, with or without CD70-fiber BsAb (0.6
mg/ml), were mock infected or infected with AdR, AdZ, or AdLacZ at
an MOI of 20. After 2 days, immunoblot assays were performed on
extracts from each sample, followed by staining with a MAb against the
early lytic EBV protein BMRF1. Staining for b-actin was used to
ensure equal sample loading.
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lignant lymphocytes, since CD70 is highly expressed in a num-
ber of hematologic malignancies (15, 27, 35, 45) but is normally
expressed on only a small subset of highly activated B and T
lymphocytes and is not detectably expressed in resting or mem-
ory lymphoid compartments or other tissue types (26). In ad-
dition, CD70-specific gene delivery could potentially be used to
regulate undesirable immune responses, for example, to pre-
vent organ transplant rejection.
A significant advantage of the BsAb approach is that ade-
novirus tropism can be redirected away from the normal target
cells and toward a specific cell type of interest. Adenovirus
vectors with a specific cellular tropism would be particularly
useful for limiting the toxicity of vectors that are intentionally
designed to kill cells. In addition, the toxicity of adenovirus
transduction to liver cells (which are CD70 negative [42]), even
in the absence of toxic gene inserts, could be minimized. How-
ever, the bispecific-antibody approach cannot prevent adeno-
virus delivery to the natural cellular receptor (CAR) unless the
fiber protein is completely bound by the bispecific antibody. In
this study, we were unable to prevent adenovirus transduction
to CD70-negative cells using the CD70-fiber bispecific anti-
body. However, the use of higher concentrations of the CD70-
fiber bispecific antibody could potentially prevent infection
through the natural CAR.
Although we were able to increase adenovirus delivery to
CD70-positive B-cell lines 10- to 20-fold by using BsAb-CD70-
fiber, we nevertheless were still unable to infect the majority of
cells. It is not clear from the present study what limits the rate
of transduction. The amount of BsAb does not appear to be
limiting, given that we used in excess of 100 molecules per
CD70 receptor, and increased BsAb did not increase transduc-
tion efficiency. Variable stoichiometry between the individual
particles within our current BsAb preparation may sterically
decrease the efficiency of binding. More likely, the amount of
surface CD70 expression, which is considerably less than the
level of CAR found on rAd-infectible cells (11, 14, 18, 32), may
be limiting. Alternatively, subsequent receptor internalization
may be inadequate in the majority of cells to support adeno-
virus entry.
In the case of EBV-associated tumors, our results suggest
that some, but not all, EBV-positive malignancies express
CD70. There are at least three different patterns of EBV gene
expression associated with malignancy (types I, II, and III),
with type I malignancies expressing the fewest EBV genes and
type III expressing the most. We found that all cell lines con-
taining the type III pattern of EBV gene expression also
showed CD70 expression, whereas the one cell line with type I
infection (the BL line Akata) did not express CD70. Similar
results have been reported by others (39). This suggests that
neither the EBV genes expressed in type I infection (charac-
terized by viral expression restricted to EBNA-1, EBERs, and
BamHI-A RNAs) nor c-myc translocation is sufficient to in-
duce CD70. EBV-positive BLs in patients commonly manifest
type I, rather than type III, infection and rarely express the
CD70 receptor (17). Nevertheless, EBV-positive malignancies
which commonly have type III infection (such as AIDS-asso-
ciated lymphomas [12], primary central nervous system lym-
phoma [16, 25], and posttransplant lymphoproliferative disease
[9]) have been shown to express the CD70 receptor in vivo. In
addition, at least one type of malignancy associated with type
II EBV infection (nasopharyngeal carcinoma) expresses CD70
as well (31). This strongly suggests that the EBV LMP-1 or
LMP-2 protein is responsible for CD70 induction (since these
viral proteins are expressed in type II and III, but not type I,
latency). In addition, the finding that nasopharyngeal carcino-
mas express CD70 suggests that EBV type II latent infection
induces CD70 expression on a cell type(s) which normally
expresses no CD70.
Our ability to increase adenovirus delivery to CD70-positive
B-cell lines 10- to 20-fold by using the CD70-fiber bispecific
antibody has already proved highly useful, since these cells are
normally resistant to adenovirus-mediated delivery. For exam-
ple, by using the BsAb technology, we were able to examine the
effect of adenovirus vectors expressing the EBV IE proteins
BZLF1 and BRLF1 in LCLs. Our laboratory had previously
shown induction of the lytic form of EBV infection in LCLs by
BZLF1 but not BRLF1 (delivered by electroporation) (50),
while another laboratory found the converse by using a vac-
cinia virus vector to deliver BZLF1 and BRLF1 (8). We show
here that efficient delivery of the gene for either BZLF1 or
BRLF1 into LCLs (which was only achieved with adenovirus
vectors by using the BsAb approach) induces the lytic form of
EBV infection. This approach could potentially be useful for
inducing specific killing of EBV-positive lymphoblastoid ma-
lignancies.
ACKNOWLEGMENTS
We thank Harald Stein for providing the Ki-24 antibody and hybrid-
oma and Veerle Laurysens at the Center for Transgene Technology
and Gene Therapy at the Catholic University of Leuven in Belgium for
purification of the 7H11 MAb. Thanks to the UNC Gene Therapy
Center for construction of AdGFP, AdZ, AdR, and AdLacZ and to
Amy E. Mauser and Jennifer J. Swenson for assistance with the prep-
aration of AdZ, AdR, and AdLacZ.
This work was supported by NIH grants R01 CA 66519 and 5-T32-
AI07151-21.
REFERENCES
1. Agathanggelou, A., G. Niedobitek, R. Chen, J. Nicholls, W. Yin, and L. S.
Young. 1995. Expression of immune regulatory molecules in Epstein-Barr
virus-associated nasopharyngeal carcinomas with prominent lymphoid
stroma. Evidence for a functional interaction between epithelial tumor cells
and infiltrating lymphoid cells. Am. J. Pathol. 147:1152–1160.
2. Agematsu, K., S. Hokibara, H. Nagumo, K. Shinozaki, S. Yamada, and A.
Komiyama. 1999. Plasma cell generation from B-lymphocytes via CD27/
CD70 interaction. Leukemia Lymphoma 35:219–225.
3. Akiba, H., H. Oshima, K. Takeda, M. Atsuta, H. Nakano, A. Nakajima, C.
Nohara, H. Yagita, and K. Okumura. 1999. CD28-independent costimula-
tion of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol.
162:7058–7066.
4. Auperin, I., J. Mikolt, E. Oksenhendler, J. B. Thiebaut, M. Brunet, B.
Dupont, and F. Morinet. 1994. Primary central nervous system malignant
non-Hodgkin’s lymphomas from HIV-infected and noninfected patients:
expression of cellular surface proteins and Epstein-Barr viral markers. Neu-
ropathol. Appl. Neurobiol. 20:243–252.
5. Bartlett, J. S., J. Kleinschmidt, R. C. Boucher, and R. J. Samulski. 1999.
Targeted adeno-associated virus vector transduction of nonpermissive cells
mediated by a bispecific F(ab9g)2 antibody. Nat. Biotechnol. 17:181–186.
6. Bashir, R., J. Luka, K. Cheloha, M. Chamberlain, and F. Hochberg. 1993.
Expression of Epstein-Barr virus proteins in primary CNS lymphoma in
AIDS patients. Neurology 43:2358–2362.
7. Blackwell, J. L., C. R. Miller, J. T. Douglas, H. Li, G. E. Peters, W. R.
Carroll, G. E. Peters, T. V. Strong, and D. T. Curiel. 1999. Retargeting to
EGFR enhances adenovirus infection efficiency of squamous cell carcinoma.
Arch. Otolaryngol.–Head Neck Surg. 125:856–863.
8. Bogedain, C., P. Alliger, F. Schwarzmann, M. Marschall, H. Wolf, and W.
Jilg. 1994. Different activation of Epstein-Barr virus immediate-early and
early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J. Virol.
68:1200–1203.
9. Brink, A. A., D. F. Dukers, A. J. van den Brule, J. J. Oudejans, J. M.
5220 ISRAEL ET AL. J. VIROL.
Middeldorp, C. J. Meijer, and M. Jiwa. 1997. Presence of Epstein-Barr virus
latency type III at the single cell level in post-transplantation lymphoprolif-
erative disorders and AIDS related lymphomas. J. Clin. Pathol. 50:911–918.
10. Curiel, T. J., D. R. Cook, C. Bogedain, W. Jilg, G. S. Harrison, M. Cotten,
D. T. Curiel, and E. Wagner. 1994. Efficient foreign gene expression in
Epstein-Barr virus-transformed human B-cells. Virology 198:577–585.
11. Defer, C., M. T. Belin, M. L. Caillet-Boudin, and P. Boulanger. 1990. Human
adenovirus-host cell interactions: comparative study with members of sub-
groups B and C. J. Virol. 64:3661–3673.
12. Diebold, J., M. Raphael, S. Prevot, and J. Audouin. 1997. Lymphomas
associated with HIV infection. Cancer Surv. 30:263–293.
13. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G.
Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with
genetically modified fibers demonstrates expanded tropism via utilization of
a coxsackievirus and adenovirus receptor-independent cell entry mechanism.
J. Virol. 72:9706–9713.
14. Goodwin, R. G., M. R. Alderson, C. A. Smith, R. J. Armitage, T. VandenBos,
R. Jerzy, T. W. Tough, M. A. Schoenborn, T. Davis-Smith, and K. Hennen.
1993. Molecular and biological characterization of a ligand for CD27 defines
a new family of cytokines with homology to tumor necrosis factor. Cell
73:447–456.
15. Gruss, H. J., and M. E. Kadin. 1996. Pathophysiology of Hodgkin’s disease:
functional and molecular aspects. Baillieres Clin. Haematol. 9:417–446. (Re-
view.)
16. Guterman, K. S., L. S. Hair, and S. Morgello. 1996. Epstein-Barr virus and
AIDS-related primary central nervous system lymphoma. Viral detection by
immunohistochemistry, RNA in situ hybridization, and polymerase chain
reaction. Clin. Neuropathol. 15:79–86.
17. Hamilton-Dutoit, S. J., D. Rea, M. Raphael, K. Sandvej, H. J. Delecluse, C.
Gisselbrecht, L. Marelle, H. J. van Krieken, and G. Pallesen. 1993. Epstein-
Barr virus-latent gene expression and tumor cell phenotype in acquired
immunodeficiency syndrome-related non-Hodgkin’s lymphoma. Correlation
of lymphoma phenotype with three distinct patterns of viral latency. Am. J.
Pathol. 143:1072–1085.
18. Henry, L. J., D. Xia, M. E. Wilke, J. Deisenhofer, and R. D. Gerard. 1994.
Characterization of the knob domain of the adenovirus type 5 fiber protein
expressed in Escherichia coli. J. Virol. 68:5239–5246.
19. Huang, R. M., M. Olsson, A. Kallin, U. Pettersson, and T. H. Totterman.
1997. Efficient adenovirus-mediated gene transduction of normal and leu-
kemic hematopoietic cells. Gene Ther. 4:1093–1099.
20. Huang, S., T. Kamata, Y. Takada, Z. M. Ruggeri, and G. R. Nemerow. 1996.
Adenovirus interaction with distinct integrins mediates separate events in
cell entry and gene delivery to hematopoietic cells. J. Virol. 70:4502–4508.
21. Huang, S., D. Stupack, A. Liu, D. Cheresh, and G. R. Nemerow. 2000. Cell
growth and matrix invasion of EBV-immortalized human B lymphocytes is
regulated by expression of alpha(v) integrins. Oncogene 19:1915–1923.
22. Huang, S., D. Stupack, P. Mathias, Y. Wang, and G. Nemerow. 1997. Growth
arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-
delivered ribozymes. Proc. Natl. Acad. Sci. USA 94:8156–8161.
23. Kenney, S., J. Q. Ge, E. M. Westphal, and J. Olsen. 1998. Gene therapy
strategies for treating Epstein-Barr virus-associated lymphomas: comparison
of two different Epstein-Barr virus-based vectors. Hum. Gene Ther. 9:1131–
1141.
24. Komano, J., M. Sugiura, and K. Takada. 1998. Epstein-Barr virus contrib-
utes to the malignant phenotype and to apoptosis resistance in Burkitt’s
lymphoma cell line Akata. J. Virol. 72:9150–9156.
25. Larocca, L. M., D. Capello, A. Rinelli, S. Nori, A. Antinori, A. Gloghini, A.
Cingolani, A. Migliazza, G. Saglio, S. Cammilleri-Broet, M. Raphael, A.
Carbone, and G. Gaidano. 1998. The molecular and phenotypic profile of
primary central nervous system lymphoma identifies distinct categories of
the disease and is consistent with histogenetic derivation from germinal
center-related B cells. Blood 92:1011–1019.
26. Lens, S. M., R. de Jong, R. Q. Hintzen, G. Koopman, R. A. van Lier, and
R. H. van Oers. 1995. CD27-CD70 interaction: unravelling its implication in
normal and neoplastic B-cell growth. Leukemia Lymphoma 18:51–59.
27. Lens, S. M., P. Drillenburg, B. F. den Drijver, G. van Schijndel, S. T. Pals,
R. A. van Lier, and M. H. van Oers. 1999. Aberrant expression and reverse
signalling of CD70 on malignant B cells. Br. J. Haematol. 106:491–503.
28. Leon, R. P., T. Hedlund, S. J. Meech, S. Li, J. Schaack, S. P. Hunger, R. C.
Duke, and J. DeGregori. 1998. Adenoviral-mediated gene transfer in lym-
phocytes. Proc. Natl. Acad. Sci. USA 95:13159–13164.
29. MacMahon, E. M., J. D. Glass, S. D. Hayward, R. B. Mann, P. S. Becker, P.
Charache, J. C. McArthur, and R. F. Ambinder. 1991. Epstein-Barr virus in
AIDS-related primary central nervous system lymphoma. Lancet 338:969–
973.
30. Nemerow, G. R., and P. L. Stewart. 1999. Role of alpha(v) integrins in
adenovirus cell entry and gene delivery. Microbiol. Mol. Biol. Rev. 63:725–
734.
31. Niedobitek, G., L. S. Young, C. K. Sam, L. Brooks, U. Prasad, and A. B.
Rickinson. 1992. Expression of Epstein-Barr virus genes and of lymphocyte
activation molecules in undifferentiated nasopharyngeal carcinomas. Am. J.
Pathol. 140:879–887.
32. Philipson, L., K. Lonberg-Holm, and U. Pettersson. 1968. Virus-receptor
interaction in an adenovirus system. J. Virol. 2:1064–1075.
33. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta
protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
J. Virol. 72:7978–7984.
34. Ragoczy, T., and G. Miller. 1999. Role of the Epstein-Barr virus RTA
protein in activation of distinct classes of viral lytic cycle genes. J. Virol.
73:9858–9866.
35. Ranheim, E. A., M. J. Cantwell, and T. J. Kipps. 1995. Expression of CD27
and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85:
3556–3565.
36. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397–2446. In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Raven
Publishers, Philadelphia, Pa.
37. Roelvink, P. W., A. Lizonova, J. G. Lee, Y. Li, J. M. Bergelson, R. W. Finberg,
D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-
adenovirus receptor protein can function as a cellular attachment protein for
adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:7909–
7915.
38. Roelvink, P. W., L. G. Mi, D. A. Einfeld, I. Kovesdi, and T. J. Wickham. 1999.
Identification of a conserved receptor-binding site on the fiber proteins of
CAR-recognizing Adenoviridae. Science 286:1568–1571.
39. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani,
and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect
novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lym-
phoma cells. EMBO J. 6:2743–2751.
40. Segal, D. M., and B. J. E. G. Bast. 1995. Production of bispecific antibodies,
p. 12.13.11–12.13.16. In J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles,
E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John
Wiley & Sons, Inc., New York, N.Y.
41. Shenk, T. 1996. Adenoviridae: the viruses and their replication, p. 2111–2171.
In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Raven
Publishers, Philadelphia, Pa.
42. Stein, H., A. Ferszt, F. Dallenbach, D. Dienemann, O. Rentrop, H. Hock, and
T Diamantstein. 1989. CDw70 mAb A109 (Ki-24): expression by reactive
and neoplastic lymphoid cells, p. 446–455; p. 495–499. In W. Knapp et al.
(ed.), Leucocyte typing IV. Oxford University Press, New York, N.Y.
43. Stevenson, S. C., M. Rollence, J. Marshall-Neff, and A. McClelland. 1997.
Selective targeting of human cells by a chimeric adenovirus vector containing
a modified fiber protein. J. Virol. 71:4782–4790.
44. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human
and mouse cellular receptors for subgroup C adenoviruses and group B
coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352–3356.
45. Trentin, L., R. Zambello, R. Sancetta, M. Facco, A. Cerutti, A. Perin, M.
Siviero, U. Basso, M. Bortolin, F. Adami, C. Agostini, and G. Semenzato.
1997. B lymphocytes from patients with chronic lymphoproliferative disor-
ders are equipped with different costimulatory molecules. Cancer Res. 57:
4940–4947.
46. Von Seggern, D. J., S. Huang, S. K. Fleck, S. C. Stevenson, and G. R.
Nemerow. 2000. Adenovirus vector pseudotyping in fiber-expressing cell
lines: improved transduction of Epstein-Barr virus-transformed B cells. J. Vi-
rol. 74:354–362.
47. Westphal, E. M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and
S. C. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in
EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Cancer Res. 59:1485–1491.
48. Wickham, T. J., G. M. Lee, J. A. Titus, G. Sconocchia, T. Bakacs, I. Kovesdi,
and D. M. Segal. 1997. Targeted adenovirus-mediated gene delivery to T
cells via CD3. J. Virol. 71:7663–7669.
49. Wickham, T. J., D. M. Segal, P. W. Roelvink, M. E. Carrion, A. Lizonova,
G. M. Lee, and I. Kovesdi. 1996. Targeted adenovirus gene transfer to
endothelial and smooth muscle cells by using bispecific antibodies. J. Virol.
70:6831–6838.
50. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral la-
tency is disrupted by the immediate-early BRLF1 protein through a cell-
specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194–9199.
VOL. 75, 2001 ADENOVIRUS INFECTION OF CD70-POSITIVE B CELLS 5221
